Adaptive Oxygen Therapeutics for Specialized Environments

Publication ID: 24-11857627_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Oxygen Therapeutics for Specialized Environments,” Published Technical Disclosure No. 24-11857627_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857627_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,627.

Summary of the Inventive Concept

An oxygen therapeutic system designed for treating glioblastoma in unique operational environments, such as high-altitude areas, disaster zones, remote locations, high-security facilities, or areas with limited medical infrastructure.

Background and Problem Solved

The original patent disclosed the use of an oxygen therapeutic in combination with repeated administrations of chemotherapy medications and/or radiation therapy. However, the existing approach may not be effective in specialized environments where oxygen levels are compromised or medical resources are limited. The new inventive concept addresses these limitations by adapting the oxygen therapeutic for use in these niche environments.

Detailed Description of the Inventive Concept

The inventive concept comprises a perfluoropentane emulsion administration module, which can be integrated with radiation therapy modules, power sources, and remote monitoring systems. The system is designed to operate in extreme weather conditions, high-altitude environments, and areas with limited medical infrastructure. The perfluoropentane emulsion is administered concomitantly with fractionated radiotherapy or chemotherapy, and the system can be adapted for secure, encrypted communication in high-security environments. The portable, self-contained treatment unit enables administration of the emulsion in disaster-stricken areas.

Novelty and Inventive Step

The new claims introduce novel adaptations of the oxygen therapeutic system for specialized environments, including high-altitude areas, disaster zones, remote locations, high-security facilities, or areas with limited medical infrastructure. The inventive step lies in the integration of the perfluoropentane emulsion administration module with radiation therapy modules, power sources, and remote monitoring systems, enabling effective treatment of glioblastoma in these unique operational environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include adapting the oxygen therapeutic system for use in other specialized environments, such as space exploration or underwater operations. Variations of the system may also include different types of oxygen therapeutics or administration methods.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the healthcare industry, particularly in areas with limited medical infrastructure or high-security environments. The system may also be of interest to government agencies, disaster relief organizations, and remote medical providers.

CPC Classifications

SectionClassGroup
A A61 A61K41/0038
A A61 A61K9/0019
A A61 A61K9/107
A A61 A61K31/02
A A61 A61K33/00
A A61 A61K39/395
A A61 A61K45/06
A A61 A61K47/10
A A61 A61K47/24
A A61 A61K47/26
A A61 A61N5/10
A A61 A61K2039/505
A A61 A61K2039/545
A A61 A61N2005/1098

Field of Art

Medical oncology and radiotherapy, specifically focused on targeted cancer treatments involving oxygen therapeutics and fractionated radiation therapy for glioblastoma, with expertise in pharmaceutical formulations, drug delivery systems, and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A medical professional with advanced training in oncology, radiotherapy techniques, pharmaceutical engineering, with knowledge of perfluorocarbon emulsions, radiation sensitization methods, and medical device adaptation for specialized environments

Obviousness Rationale

A PHOSITA would recognize that adapting the perfluoropentane emulsion treatment method to different operational environments represents a predictable engineering variation that leverages the core therapeutic mechanism disclosed in the source patent. The fundamental chemical and medical principles remain consistent, with modifications primarily addressing deployment and operational constraints. The variations represent logical extensions of the original therapeutic approach, applying known design principles to expand treatment accessibility.

Obvious Combinations & Variations

Source Patent Element
Intravenous perfluoropentane emulsion administration for glioblastoma treatment
PTD Variation
Portable, self-contained treatment unit for administering emulsion in disaster zones or remote locations
Obviousness Reasoning
A PHOSITA would find it obvious to modify the delivery mechanism to enable treatment in resource-constrained environments, using standard medical engineering techniques for portable medical systems
Source Patent Element
Fractionated radiotherapy with perfluoropentane emulsion
PTD Variation
High-altitude environment adaptation of oxygen therapeutic system
Obviousness Reasoning
Adjusting emulsion formulation and delivery for low-oxygen conditions represents a predictable design modification using known pharmaceutical engineering principles
Source Patent Element
Chemotherapy and radiation therapy combination with oxygen therapeutic
PTD Variation
Secure, encrypted communication system for treatment administration in high-security environments
Obviousness Reasoning
Integrating communication technologies with medical treatment represents a standard engineering approach for expanding treatment protocol flexibility
Source Patent Element
Perfluoropentane emulsion with 1-5% concentration
PTD Variation
Alternative oxygen therapeutic formulations for specialized environments
Obviousness Reasoning
Exploring variant formulations within established concentration ranges is a routine optimization strategy for a skilled practitioner
Source Patent Element
Glioblastoma treatment method using radiation sensitization
PTD Variation
Adaptation for space exploration or underwater medical treatment scenarios
Obviousness Reasoning
Extending medical treatment protocols to extreme environments is a predictable engineering challenge with known systematic approaches
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857627, the variations disclosed herein would be obvious to a Person Having Ordinary Skill In The Art, as they represent predictable engineering adaptations of an established therapeutic method. The disclosed variations extend the original oxygen therapeutic approach through standard design modifications that would be apparent to a skilled practitioner, thereby rendering potential derivative claims non-patentable under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,627
TitleFractionated radiotherapy and chemotherapy with an oxygen therapeutic
Assignee(s)NuvOx Pharma LLC